Last checked at 1 Jul 2021 07:00
1 July 2021
Diaceutics PLC
("Diaceutics" or "the Company")
Issue of Share Options and PDMR Shareholdings
Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company for precision testing announces the issue of share options over ordinary shares of £0.002 each in the Company ("Share Options") on 30 June 2021, to certain members of the Company's senior management team and other key staff. These share options have been issued pursuant to certain contractual share-based entitlements in place prior to the Company's IPO and are governed by the rules of the Company's Employee Share Option Plan ("ESOP").
Share Options were granted as follows:
Name | Number of Share Options granted | Total no. of ordinary shares under option post grant | % of existing issued share capital |
Damian Thornton (COO and PDMR) | 4,200 | 170,996 | 0.2% |
Susanne Munksted (CPO and PDMR) | 4,200 | 70,672 | 0.08% |
A further 147,000 Share Options were granted to 35 employees, each of whom received 4,200 Share Options.
The Share Options vest in full after three years following date of grant subject to the grantee receiving no more than two "unsatisfactory" performance ratings in their individual performance reviews in the three-year period from the date of grant. The exercise price of the Share Options is £0.002 per share being the nominal value of the share.
Following the grant the total number of share options outstanding granted to the Company's Directors, senior management team and key employees is 2,237,170, representing approximately 2.7% of the Company's current issued share capital of 84,068,923.
Enquiries:
Diaceutics PLC |
|
Philip White, Chief Financial Officer | Via Alma PR |
|
|
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison |
|
Stewart Wallace |
|
Nick Adams |
|
|
|
Alma PR | Tel: +44(0)20 3405 0205 |
Caroline Forde | diaceutics@almapr.co.uk |
Robyn Fisher |
|
Kieran Breheny |
|
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Damian Thornton | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chief Operating Officer | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Grant of Share Options | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) | Volume(s) |
| ||||
£0.002 | 4,200 |
| |||||
| |||||||
d. | Date of the transaction | 30 June 2021 | |||||
e. | Place of the transaction | Outside a Trading Venue | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Susanne Munksted | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chief Precision Officer | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Grant of Share Options | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) | Volume(s) |
| ||||
£0.002 | 4,200 |
| |||||
| |||||||
d. | Date of the transaction | 30 June 2021 | |||||
e. | Place of the transaction | Outside a Trading Venue | |||||